Bruker Acquires Majority Stake in RECIPE, Boosts Diagnostic and Drug Monitoring Capabilities

Bruker Corporation (NASDAQ:BRKR) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 3, Bruker Corporation (NASDAQ:BRKR) acquired a majority investment in RECIPE, a manufacturer of diagnostic assays, marking a substantial step in the applied markets. The company also introduced the timsMetabo platform for advanced small molecule analysis.

Bruker’s therapeutic drug monitoring (TDM) and drugs of abuse (DoA) analysis capabilities are improved by the investment in RECIPE. The two companies’ cooperation has resulted in the integration of Bruker’s EVOQ DART-TQ system with RECIPE’s ClinMass and ClinDART test kits. Although not yet US-FDA authorized, these kits are made to provide high-throughput, chromatography-free tests that can be utilized in laboratory-developed testing (LDT) methodologies.

Bruker Applied Mass Spectrometry Senior Vice President Jeffrey Zonderman stressed the importance of these advancements in redefining the capabilities in applied industries, particularly for environmental analysis and TDM.

Bruker Corporation (NASDAQ:BRKR), a leading American manufacturer of high-performance scientific equipment, focuses on tools for molecular and materials research, as well as industrial analysis.

While we acknowledge the potential of BRKR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.